ESWT applied with SANUWAVE’s Ossatron device results in 80% healing rate of nonunions of the tibia

SANUWAVE Health, Inc., (OTC BB: SNWV) (www.sanuwave.com), an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, today announced that a journal article titled Extracorporeal Shock Wave Therapy for Nonunion of the Tibia, was published in the March 2010 issue of the Journal of Orthopedic Trauma. Based on the results of the study, the authors suggest that non-invasive Extracorporeal Shock Wave Technology (ESWT) applied with SANUWAVE’s Ossatron® device with one treatment session of 4000 pulses followed by fracture immobilization resulted in an 80% rate of healing of the nonunion bone fractures (incomplete fracture healing) as assessed by both clinical and radiographic means.

The authors of the study, Elster E., Stojadinovic A., Forsberg J., Shawen S., Andersen R. and Schaden W., represent the National Naval Medical Center, Naval Medical Research Center, Walter Reed Army Medical Center and AUVA Trauma Center in Vienna, Austria. The journal article detailed a 6-year study that included 172 patients undergoing treatment for tibia nonunion utilizing SANUWAVE’s Ossatron® device. The majority of patients referred to the study for tibia nonunion were resistant or unresponsive to one or more surgical treatments. Median time to healing from last orthopaedic operation was 14 months with a mean follow-up of nearly 16 months. The average time to healing after ESWT was 4.8 months. The authors stated that although the precise mechanism of targeted physical energy to produce the desired biologic effect of bone healing is not completely understood, migration and differentiation of mesenchymal stem cells (multipoint stem cells that can differentiate into a variety of cell types), and promotion of angiogenesis are thought to contribute increased bone mass and strength.

SANUWAVE expects to introduce a new commercial device to European markets called the orthoPACE™ that is capable of treating in an equivalent energy range utilized in this study. Scheduled to be launched during the second quarter of 2010, the orthoPACE™ has a compact, portable design and allows for treatments to be performed by a single operator in both the hospital and office setting. The orthoPACE™ replaces SANUWAVE’s Ossatron®, the 800 lb. legacy device that was used in this study. The orthoPACE™ will be indicated for a wide range of orthopedic, sports medicine and trauma indications including acute and nonunion fracture treatment.

In the U.S., 6,000,000 traumatic fractures are treated each year, and the prevalence of nonunion among these fractures is between 2.5% and 10.0% depending on the fracture type.

SANUWAVE President and CEO, Christopher M. Cashman said, “This comprehensive study, which reports an 80% healing rate of nonunions of the tibia, supports the utilization of PACE™ technology in the orthopedic space beyond the well-established treatment of chronic tendinopathies. We are looking forward to our expected second quarter launch of orthoPACE™ in Europe, where our growing base of distribution partners can continue to expand the use of PACE™ technology. The orthoPACE™ can be used across multiple care settings which we expect will increase the number of patients who are treated in a convenient, non-invasive and cost-effective way.”

Mr. Cashman concluded, “In addition to the important fracture healing results of this tibia study, SANUWAVE anticipates releasing the results of its U.S. Phase IIb Investigational Device Exemption (IDE) study focused on extremity small bone nonunion or delayed healing fracture in the second quarter of this year. SANUWAVE’s strategy for orthoPACE™ in the U.S. is to focus our clinical efforts and FDA submissions on the $4.2 billion orthopedic repair market.”

Source SANUWAVE Health, Inc.